Top

Cancer Chemotherapy and Pharmacology

Published in:

01-03-2019 | Original Article

A retrospective study of the CHOP, CHOPE, and CHOPE/G regimens as the first-line treatment of peripheral T-cell lymphomas

Authors: Xuyan Liu, Mingzi Yang, Meng Wu, Wen Zheng, Yan Xie, Jun Zhu, Yuqin Song, Weiping Liu

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2019

Abstract

Purpose

The standard treatment for peripheral T-cell lymphomas (PTCLs) is undetermined. We designed a CHOPE/G regimen (cyclophosphamide, pirarubicin, vincristine, prednisolone, and etoposide alternating with a gemcitabine-based regimen) as the first-line treatment of PTCLs and compared with CHOP (cyclophosphamide, pirarubicin, vincristine, and prednisolone) and CHOPE (CHOP plus etoposide) regimen to evaluate the optimal chemotherapy regimen.

Methods

116 previously untreated PTCL patients received CHOP (N = 46), CHOPE (N = 46), or CHOPE/G (N = 24) regimen at Peking University Cancer Hospital from 2009 to 2017 and were retrospectively analyzed.

Results

The overall response rates (ORRs) of the CHOP, CHOPE, and CHOPE/G groups were 82.6%, 76.1%, and 75.0% (p = 0.673), with complete response (CR) rates of 32.6%, 56.5%, and 45.7% (p = 0.063), respectively. Within a median follow-up time of 35.5 months, the 3-year overall survival (OS) rates of the CHOP, CHOPE, and CHOPE/G groups were 37.0%, 47.0%, and 56.3% (p = 0.107), and the 3-year progression-free survival (PFS) rates were 19.9%, 29.9%, and 5.3% (p = 0.093), respectively. Compared with the CHOP regimen alone, CHOPE had a significantly higher CR rate (p = 0.021) with more favorable OS (p = 0.046). The CHOPE/G regimen did not improve the ORR, CR rate, or OS compared with either the CHOP or CHOPE, with a significantly poorer PFS compared with the CHOPE regimen (p = 0.029). Anemia and thrombocytopenia occurred most frequently in the CHOPE/G group (anemia 83.3%, p = 0.035; thrombocytopenia 50%, p = 0.015).

Conclusions

Compared with CHOP alone, CHOPE regimen improved the efficacy and survival; while the addition of gemcitabine in the front-line therapy resulted in more adverse events without benefit of survival.

Shankland KR, Armitage JO, Hancock BW (2012) Non-Hodgkin lymphoma. Lancet 380(9844):848–857. https://doi.org/10.1016/S0140-6736(12)60605-9 CrossRefPubMed

Ascani S, Zinzani PL, Gherlinzoni F et al (1997) Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. classification. Ann Oncol 8(6):583–592. https://doi.org/10.1023/A:1008200307625 CrossRefPubMed

Morton LM, Wang SS, Devesa SS et al (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 107(1):265–276. https://doi.org/10.1182/blood-2005-06-2508 CrossRefPubMedPubMedCentral

Chihara D, Ito H, Matsuda T et al (2014) Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol 164(4):536–545. https://doi.org/10.1111/bjh.12659 CrossRefPubMed

Park S, Ko YH (2014) Peripheral T cell lymphoma in Asia. Int J Hematol 99(3):227–239. https://doi.org/10.1007/s12185-014-1520-3 CrossRefPubMed

Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390. https://doi.org/10.1182/blood-2016-01-643569 CrossRefPubMedPubMedCentral

Vose J, Armitage J, Weisenburger D (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26(25):4124–4130. https://doi.org/10.1200/JCO.2008.16.4558 CrossRefPubMed

National Comprehensive Cancer Network (2018) Lymphomas T-Cell (Version 5) https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf. Accessed 13 Aug 2018

Ellin F, Landstrom J, Jerkeman M et al (2014) Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 124(10):1570–1577. https://doi.org/10.1182/blood-2014-04-573089 CrossRefPubMed

10.

Schmitz N, Trümper L, Ziepert M et al (2010) Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German high-grade non-Hodgkin Lymphoma Study Group. Blood 116(18):3418–3425. https://doi.org/10.1182/blood-2010-02-270785 CrossRefPubMed

11.

Nickelsen M, Ziepert M, Zeynalova S et al (2009) High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German high-grade non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol 20(12):1977–1984. https://doi.org/10.1093/annonc/mdp211 CrossRefPubMed

12.

Escalón MP, Liu NS, Yang Y et al (2005) Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 103:2091–2098. https://doi.org/10.1002/cncr.20999 CrossRefPubMed

13.

Dunleavy K, Pittaluga S, Shovlin M et al (2016) Phase II trial of dose adjusted EPOCH in untreated systemic anaplastic large cell lymphoma. Haematologica 101:e27–e29. https://doi.org/10.3324/haematol.2015.131151 CrossRefPubMedPubMedCentral

14.

Zinzani PL, Venturini F, Stefoni V et al (2010) Gemcitabine as single agent in pretreated T cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 21(4):860–863. https://doi.org/10.1093/annonc/mdp508 CrossRefPubMed

15.

Arkenau HT, Chong G, Cunningham D et al (2007) Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 92(2):271–272. https://doi.org/10.3324/haematol.10737 CrossRefPubMed

16.

Dong M, He XH, Liu P et al (2013) Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma. Med Oncol 30(1):351. https://doi.org/10.1007/s12032-012-0351-4 CrossRefPubMed

17.

Jia B, Hu S, Yang J et al (2016) Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas. Hematology 21(9):536–541. https://doi.org/10.1080/10245332.2016 CrossRefPubMed

18.

Kim JG, Sohn SK, Chae YS et al (2006) CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol 58(1):35–39. https://doi.org/10.1007/s00280-005-0136-y CrossRefPubMed

19.

Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, Fourth edn. IARC WHO Classification of Tumours, No 2

20.

Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068. https://doi.org/10.1200/JCO.2013.54.8800 CrossRefPubMedPubMedCentral

21.

Rüdiger T, Weisenburger DD, Anderson JR et al (2002) Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-Hodgkin’s Lymphoma Classification Project. Ann Oncol 13(1):140–149. https://doi.org/10.1093/annonc/mdf033 CrossRefPubMed

22.

Xie W, Hu K, Xu F et al (2013) Significance of clinical factors as prognostic indicators for patients with peripheral T-cell non-Hodgkin lymphoma: a retrospective analysis of 252 cases. Mol Clin Oncol 1(5):911–917. https://doi.org/10.3892/mco.2013.146 CrossRefPubMedPubMedCentral

23.

Mahadevan D, Unger JM, Spier CM et al (2013) Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 119(2):371–379. https://doi.org/10.1002/cncr.27733 CrossRefPubMed

24.

Gleeson M, Peckitt C, To YM et al (2018) CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. Lancet Haematol 5(5):e190–e200. https://doi.org/10.1016/S2352-3026(18)30039-5 CrossRefPubMedPubMedCentral

Title: A retrospective study of the CHOP, CHOPE, and CHOPE/G regimens as the first-line treatment of peripheral T-cell lymphomas
Authors: Xuyan Liu
Mingzi Yang
Meng Wu
Wen Zheng
Yan Xie
Jun Zhu
Yuqin Song
Weiping Liu
Publication date: 01-03-2019
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2019
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3744-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2019

Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells

Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors

Prophylactic effect of scopolamine butylbromide, a competitive antagonist of muscarinic acetylcholine receptor, on irinotecan-related cholinergic syndrome

Dose-dense paclitaxel/carboplatin as neo-adjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer: a prospective phase II study

Evaluation of the effects of an oral notch inhibitor, crenigacestat (LY3039478), on QT interval, and bioavailability studies conducted in healthy subjects

Targeting neratinib-induced diarrhea with budesonide and colesevelam in a rat model

Keynote webinar | Spotlight on antibody–drug conjugates in cancer